12 Best UK Stocks to Buy According to Hedge Funds

8. Roivant Sciences Ltd. (NASDAQ:ROIV)

On March 19, 2026, Bernstein initiated coverage of Roivant Sciences Ltd. (NASDAQ:ROIV) with an Outperform rating and a $35 price target, citing potential upside from upcoming clinical readouts in pulmonary hypertension associated with interstitial lung disease and non-infectious uveitis. The firm noted risks around competitive data and launch execution, but said these concerns appear “appropriately discounted.”

Earlier in March, JPMorgan raised its price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $33 from $31 previously and maintained an Overweight rating after updating its model to reflect the company’s settlement with Moderna. JPMorgan described the agreement as a “major overhang lift,” shifting investor focus toward upcoming clinical catalysts.

H.C. Wainwright also raised its price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $34 from $33 previously and reiterated a Buy rating, incorporating $2.25B in litigation proceeds tied to a global settlement between Roivant subsidiary Genevant Sciences, Arbutus Biopharma, and Moderna related to lipid nanoparticle delivery technology.

Roivant Sciences Ltd. (NASDAQ:ROIV) develops and commercializes biopharmaceutical products across multiple therapeutic areas.